• 1
    Ogedegbe G, Harrison M, Robbins L, et al. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis. 2004;14:312.
  • 2
    Carter BL. Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. Am J Health Syst Pharm. 1998;55(suppl 3):1723.
  • 3
    Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352358.
  • 4
    Hermida RC, Ayala DE, Fernandez JR, et al. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011;24:383391.
  • 5
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:23132321.
  • 6
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011;58:11651173.
  • 7
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:12701276.
  • 8
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012;25:325334.
  • 9
    Veerman DP, Imholz BP, Wieling W, et al. Circadian profile of systemic hemodynamics. Hypertension. 1995;26:5559.
  • 10
    Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:24072415.
  • 11
    Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49:12351241.
  • 12
    Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:5561.
  • 13
    Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793801.
  • 14
    Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51:6976.
  • 15
    Sturrock ND, George E, Pound N, et al. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med. 2000;17:360364.
  • 16
    Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53:2027.
  • 17
    Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:13151322.
  • 18
    Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:15141518.
  • 19
    Applegate WB, Borhani N, DeQuattro V, et al. Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring. Am J Med. 1991;90:198205.
  • 20
    Hornung RS, Gould BA, Kieso H, Raftery EB. A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing. Br J Clin Pharmacol. 1982;14:8388.
  • 21
    Raftery EB, Mann S, BalaSubramanian V, Craig MW. Once-daily pindolol in hypertension: an ambulatory assessment. Am Heart J. 1982;104:417420.
  • 22
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:16291651.
  • 23
    American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(suppl 1):S11S66.
  • 24
    Smolensky MH, Haus E. Circadian rhythms and clinical medicine with applications to hypertension. Am J Hypertens. 2001;2:280S290S.
  • 25
    Eldon MA, Battle MM, Voigtman RE, Colburn WA. Differences in oral verapamil absorption as a function of time of day. J Clin Pharmacol. 1989;29(11):989993.
  • 26
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Sleep-time blood pressure and the prognostic value of isolated-office and masked hypertension. Am J Hypertens. 2012;25:297305.
  • 27
    Palatini P, Racioppa A, Raule G, et al. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther. 1992;52:378383.
  • 28
    Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev.2011 Oct 5;(10):CD004184.
  • 29
    Rahman M, Greene T, Phillips RA, et al. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013;61:8288.
  • 30
    Basile JN, Bloch MJ. Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease. J Clin Hypertens. 2013;15:24.
  • 31
    Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603624.
  • 32
    Hayreh SS, Podhajsky PA, Zimmerman B. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol. 1997;124:641647.
  • 33
    Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica. 1999;213:7696.
  • 34
    Krasinska B, Karolczak-Kulesza M, Krasinski Z, et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press. 2012;21:240248.
  • 35
    Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010;304:793794.
  • 36
    Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15:9096.
  • 37
    de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004;13:311320.
  • 38
    Centers for Disease Control and Prevention. Measuring Health Days. Atlanta, GA: Centers for Disease Control and Prevention; 2000.
  • 39
    Dominick KL, Ahern FM, Gold CH, Heller DA. Relationship of health-related quality of life to health care utilization and mortality among older adults. Aging Clin Exp Res. 2002;14:499508.
  • 40
    Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord. 1998;13:406413.